Figure 1From: A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin Change in WOMAC Pain Scores/100 by Visit and Study Group. Statistical significant changes from baseline were observed during the 90 day study with UP446 500 mgs/day group reaching significance earlier at 30 days.Back to article page